Floatz logo

Stemex®

Hodgkin's Disease

Gamida Cell -Teva Joint Venture Ltd.Phase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

150 Active assets in the Hodgkin's Disease cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 3BBB
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB
Everolimus
OHSU Knight Cancer Institute
Phase 2BBB
Cytosin-Arabinosid
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB

View all 50 →

Same molecule, other indications

Stemex® is also rated in:

lymphoid leukemiaDormant
B
Indicative ·
61 / 100
View asset →
chronic myeloid leukemiaDormant
B
Indicative ·
58 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →